Scientific Programme
Fourteen sessions over the three days of the international programme (Days 2, 3 and 4), each opening with a debate and closing with discussion, alongside satellite symposia, oral abstract presentations and a Pre-Dinner Summary and Thoughts on Day closing each evening.
Istanbul MS Days XI — Scientific Programme
30 March – 3 April 2027 · Papillon Zeugma Resort, Belek, Antalya, Türkiye
Day 1 — 30 March 2027
All sessions on this day will be held in Turkish, except for the Young Investigators & European Charcot Foundation Fellowship Community Special Session.
-
13:00-14:30
-
14:30-15:15
- 15:15-15:30 Coffee BreakKahve Arası
-
15:30-17:00
-
17:00-17:45
- 17:45-18:00 Coffee BreakKahve Arası
-
18:00-19:00
-
19:00-20:00
Panel IV
-
19:00-19:20
Will new advances in neuroimmunology change the immunopathogenesis of MS?
Nöroimmünolojideki yeni gelişmeler MS immünopatogenezini değiştirecek mi?
-
19:20-19:40
What might PET studies change in how we understand and approach MS?
PET çalışmaları MS’yi anlama ve yaklaşımımızda neleri değiştirebilir?
-
19:40-20:00
How will artificial intelligence affect the diagnosis and treatment of MS in the future?
Yapay zekâ gelecekte MS tanı ve tedavisini nasıl etkileyecek?
-
19:00-19:20
-
20:00-20:15
Day 2 — 31 March 2027
-
09:00-10:30
Official Opening & Presentation of the Istanbul MS Days Award
-
09:00-09:20
Opening Ceremony
- 5-minute inspirational video “Patients’ Voice: What do our patients expect from us?”
- Short comments on the video by Rana Karabudak and Hüsnü Efendi
-
09:20-09:35
Welcome address 1
Tree of Life: The interconnected roots of existence
Orhun Kantarci
-
09:35-09:50
Welcome address 2
From roots to fruits in MS & Autoimmunity
Aksel Siva
-
09:50-10:00
Presentation of the Istanbul MS Days 2027 Award
Hüsnü Efendi, Orhun Kantarci, Rana Karabudak, Aksel Siva
-
10:00-10:30
2027 Istanbul MS Days Award Lecture
How to rejuvenate the nervous system: Roots up or branches down
Catherine Lubetzki
-
09:00-09:20
- 10:30-10:45 Coffee break
-
10:45-12:20Session 1
Seeds of MS
Chairs & discussantsEda Tahir Turanlı, Ellen Mowry, Anthony Traboulsee
-
10:45-11:00
Introductory debate
Is inheritance of MS genetic or epigenetic?
ModeratorEda Tahir Turanlı
Genetic Anthony TraboulseeEpigenetic Ellen MowryFollowed by an electronic live voting
-
11:00-11:20
Genetic risk of MS is underestimated
Philip L. De Jager
-
11:20-11:40
Epigenetic inheritance of MS shapes diversity in MS outcomes
Nabeela Nathoo
-
11:40-12:00
Is EBV the only trigger of MS or tip of the iceberg?
Alberto Ascherio
-
12:00-12:20
Q&A and discussion
-
10:45-11:00
-
12:20-13:45
-
13:45-15:20Session 2
Seeds to Initial Roots of MS
Chairs & discussantsDimitrios Karussis, Batu Erman, Anat Achiron
-
13:45-14:00
Introductory debate
Does the immune system have a master regulatory cell?
ModeratorDimitrios Karussis
Yes Anat AchironNo Batu ErmanFollowed by an electronic live voting
-
14:00-14:20
Tregs matter in MS
David Hafler
-
14:20-14:40
Bregs matter more than Tregs in MS
Andrew Chan
-
14:40-15:00
Ingress of the Innate: monocyte lineage in MS immune regulation
Amit Bar-Or
-
15:00-15:20
Q&A and discussion
-
13:45-14:00
- 15:20-15:35 Coffee break
-
15:35-17:10Session 3
Establishing the Root System in MS
Chairs & discussantsBoris Zalc, Romana Höftberger, Jack Antel
-
15:35-15:50
Introductory debate
Does the CNS have a master regulatory cell?
ModeratorJack Antel
Yes Boris ZalcNo Romana HöftbergerFollowed by an electronic live voting
-
15:50-16:10
Ependymal Cells: The Glass Child of CNS Glia
Bruce Trapp
-
16:10-16:30
Oligodendrocytes: Between a rock and a hard place
V. Wee Yong
-
16:30-16:50
Microglia: Master of cells or Orion?
Laura Airas
-
16:50-17:10
Q&A and discussion
-
15:35-15:50
- 17:10-17:25 Coffee break
-
17:25-19:00Session 4
Connecting the Root System in MS
Chairs & discussantsSerkan Demir, Vilas Menon, Darin Okuda
-
17:25-17:40
Introductory debate
AI will reshape our understanding of MS & autoimmunity
ModeratorSerkan Demir
Yes Vilas MenonNo Darin OkudaFollowed by an electronic live voting
-
17:40-18:00
How to build AI into the future of medical education
Janet Hafler
-
18:00-18:20
Using AI to solve the unsolvable: Examples from the real world
Mika Gustafsson
-
18:20-18:40
Using the roots rather than the fruits of disease to redefine the phenotypes of MS: An AI-based approach
Heinz Wiendl
-
18:40-19:00
Q&A and discussion
-
17:25-17:40
-
19:00-19:30
Day 3 — 1 April 2027
-
08:00-08:50
-
09:00-10:35Session 5
Clinical Branches of MS
Chairs & discussantsMagd Zakaria, Ludwig Kappos, Brian Weinshenker
-
09:00-09:15
Introductory debate
Does MS have distinct phases?
ModeratorMagd Zakaria
Yes Brian WeinshenkerNo Ludwig KapposFollowed by an electronic live voting
-
09:15-09:35
All relapses are equal, but some relapses are more equal than others
Darin Okuda
-
09:35-09:55
The biology of progressive MS is a continuum that starts from the beginning
Daniel Ontaneda
-
09:55-10:15
The makeup of cumulative disability in MS: Why do we see “benign” and severe extremes?
Christina J. Azevedo
-
10:15-10:35
Q&A and discussion
-
09:00-09:15
- 10:35-10:50 Coffee break
-
10:50-12:25Session 6
Imaging Branches and Fruits of MS
Chairs & discussantsSerhat Okar, Bruno Stankoff, Daniel Reich
-
10:50-11:05
Introductory debate
Molecular imaging is as important as MRI for understanding the progressive MS phenotype
ModeratorSerhat Okar
Yes Bruno StankoffNo Daniel ReichFollowed by an electronic live voting
-
11:05-11:25
After the acute phase, some lesions continue to evolve: Smoldering and slowly expanding lesions in the CNS
Susan Gauthier
-
11:25-11:45
MS is a diffuse slow burn within the CNS: The smoldering brain and atrophy at distant sites
Burcu Zeydan
-
11:45-12:05
Skull bone marrow in MS: Lessons from TSPO-PET
Caterina Mainero
-
12:05-12:25
Q&A and discussion
-
10:50-11:05
-
12:25-13:50
-
13:50-15:35Session 7
Ripening the Fruits of MS
Chairs & discussantsNur Yüceyar, Emmanuelle Waubant, Sandra Vukusic
-
13:50-14:05
Introductory debate
Is it time to consider sex hormone-based therapy in MS?
ModeratorNur Yüceyar
Yes Emmanuelle WaubantNo Sandra VukusicFollowed by an electronic live voting
-
14:05-14:25
Mixing and matching sex chromosomes to dissect their impact on autoimmunity and MS
Manu Rangachari
-
14:25-14:45
Too much or too little? How female hormones shape MS across the reproductive lifespan
Kerstin Hellwig
-
14:45-15:05
How do male sex hormones impact MS?
Riley Bove
-
15:05-15:35
Q&A and discussion
-
13:50-14:05
- 15:35-15:50 Coffee break
-
15:50-17:25Session 8
Harvesting better outcomes in MS starts with early diagnosis
Chairs & discussantsHüsnü Efendi, Xavier Montalban, Bassem Yamout
-
15:50-16:05
Introductory debate
Will earlier diagnosis using the 2024 McDonald criteria meaningfully reduce long-term disability in MS?
ModeratorHüsnü Efendi
Yes Xavier MontalbanNo Bassem YamoutFollowed by an electronic live voting
-
16:05-16:25
The multiple sclerosis diagnostic tree re-envisioned: New roots and branches
Ellen Mowry
-
16:25-16:45
Imaging gold standards for validating MS diagnostic criteria: Lessons from RIS and beyond, with potential implications for treatment outcomes
Christine Lebrun-Frénay
-
16:45-17:05
How should MS diagnostic criteria best be validated from a statistical perspective?
Maria Pia Sormani
-
17:05-17:25
Q&A and discussion
-
15:50-16:05
- 17:25-17:40 Coffee break
-
17:40-19:15Session 9
Grafting the MS tree to bear a different fruit
Chairs & discussantsJiwon Oh, Hans Lassmann, Hans-Peter Hartung
-
17:40-17:55
Introductory debate
Can directly targeting microglia meaningfully improve outcomes in MS?
ModeratorHans-Peter Hartung
Yes Jiwon OhNo Hans LassmannFollowed by an electronic live voting
-
17:55-18:15
CAR-T cell therapy in MS: What could it offer beyond current treatments, and at what risk?
Refik Pul
-
18:15-18:35
Where are the promised remyelination therapies for MS?
Thomas Berger
-
18:35-18:55
Can endogenous neural stem and progenitor cells be mobilized for CNS repair in MS?
Orhan Aktaş
-
18:55-19:15
Q&A and discussion
-
17:40-17:55
-
19:15-19:45
- 19:45-20:00 Pre-dinner break
Day 4 — 2 April 2027
-
08:00-08:45
-
09:00-10:35Session 10
Describing what to pick better in MS
Chairs & discussantsAxel Petzold, Thomas Berger, Mohammad Ali Sahraian
-
09:00-09:15
Introductory debate
We already have pretty good clinical, biofluid and imaging biomarkers: Do we still need more biomarkers for MS?
ModeratorMohammad Ali Sahraian
Yes Axel PetzoldNo Thomas BergerFollowed by an electronic live voting
-
09:15-09:35
Unmet needs in imaging biomarkers for MS
Nicola De Stefano
-
09:35-09:55
Unmet needs in blood biomarkers for MS
Hayrettin Tumani
-
09:55-10:15
Unmet needs in CSF biomarkers for MS
Eric Thouvenot
-
10:15-10:35
Q&A and discussion
-
09:00-09:15
- 10:35-10:50 Coffee break
-
10:50-12:25Session 11
Picking the hard-to-reach fruits in MS
Chairs & discussantsYeşim Beckman, Maria Matilde Inglese, Riadh Gouider
-
10:50-11:05
Introductory debate
Cognitive and behavioral impairment is the most common and prominent disability in MS
ModeratorYeşim Beckman
Yes Maria Matilde IngleseNo Riadh GouiderFollowed by an electronic live voting
-
11:05-11:25
Cognitive disability starts very early in MS
Naila Makhani
-
11:25-11:45
Radiomic features of cognitive impairment can be seen long before patients report symptoms
Korhan Büyüktürkoğlu
-
11:45-12:05
The hidden roots of cognitive impairment in MS: From cellular pathology to network failure
Tanja Kuhlmann
-
12:05-12:25
Q&A and discussion
-
10:50-11:05
-
12:25-13:50
-
13:50-15:25Session 12
Mimics of MS — From Roots to Fruits
Chairs & discussantsMelih Tütüncü, Uğur Uygunoğlu, Romain Marignier
-
13:50-14:05
Introductory debate
Can autoimmune mimics of MS be reliably distinguished from MS?
ModeratorRomain Marignier
Yes Melih TütüncüNo Uğur UygunoğluFollowed by an electronic live voting
-
14:05-14:25
Neurosarcoidosis: The orphaned mimic of CNS autoimmunity
Orhun Kantarci
-
14:25-14:45
Diagnosing without a gold standard: Do we need better criteria for Neuro-Behçet disease?
Aksel Siva
-
14:45-15:05
Other autoimmune mimics of MS, NMOSD and MOGAD
Eoin Flanagan
-
15:05-15:25
Q&A and discussion
-
13:50-14:05
- 15:25-15:40 Coffee break
-
15:40-17:15Session 13
From seeds to fruits in NMOSD
Chairs & discussantsNasrin Asgari, Ayşe Altıntaş, Melinda Magyari
-
15:40-15:55
Introductory debate
Is AQP4-IgG-positive NMOSD our best model for precision therapy in CNS autoimmunity?
ModeratorMelinda Magyari
Yes Nasrin AsgariNo Ayşe AltıntaşFollowed by an electronic live voting
-
15:55-16:15
What do longitudinal changes in AQP4-IgG and MOG-IgG really tell us about prognosis and treatment?
Tania Kümpfel
-
16:15-16:35
Beyond attack prevention in NMOSD: What remains unmet in treatment, recovery and long-term outcomes?
Kazuo Fujihara
-
16:35-16:55
What lies behind double-seronegative NMOSD: A distinct disease entity or a heterogeneous group of disorders?
Paulus Rommer
-
16:55-17:15
Q&A and discussion
-
15:40-15:55
- 17:15-17:30 Coffee break
-
17:30-19:05Session 14
From seeds to fruits in MOGAD
Chairs & discussantsNajib Kissani, Silvia Tenembaum, Rana Karabudak
-
17:30-17:45
Introductory debate
Is MOGAD primarily a post-infectious autoimmune disease of the CNS?
ModeratorNajib Kissani
Yes Silvia TenembaumNo Rana KarabudakFollowed by an electronic live voting
-
17:45-18:05
How common is MOGAD, really?
Zsolt Illés
-
18:05-18:25
From antibodies and cellular mechanisms to clinical outcomes: The biology of MOGAD
Anne-Katrin Pröbstel
-
18:25-18:45
The treatment saga in MOGAD: Whom to treat, when to start, what to use and for how long?
Romain Marignier
-
18:45-19:05
Q&A and discussion
-
17:30-17:45
-
19:05-19:35
-
19:35-19:50
- 19:50-20:15 Pre-dinner break
Day 5 — 3 April 2027
The sessions on this day are held in Turkish.
-
09:30-11:00
- 11:00-11:15 Coffee BreakKahve Arası
-
11:15-12:15
-
12:15-12:45
-
12:45-13:00